Fiscal Second Quarters Ended (Dollars in Millions) June 28, 2015 June 29, 2014 Percent Change Consumer (1) $ 317 703 (54.9 )% Pharmaceutical (2) 4,122 3,469 18.8 Medical Devices (3) 1,584 1,703 (7.0 ) Segments operating profit 6,023 5,875 2.5 Less: Expense not allocated to segments (4) 282 249 Worldwide income before taxes $ 5,741 5,626 2.0 % Fiscal Six Months Ended (Dollars in Millions) June 28, 2015 June 29, 2014 Percent Change Consumer (1) $ 961 1,181 (18.6 )% Pharmaceutical (2) 7,084 6,674 6.1 Medical Devices (3) 3,805 3,670 3.7 Segments operating profit 11,850 11,525 2.8 Less: Expense not allocated to segments (4) 534 475 Worldwide income before taxes $ 11,316 11,050 2.4 % (1) Includes a gain of $332 million from the divestiture of the K-Y ® brand recorded in the fiscal second quarter and first fiscal six months of 2014. (2) Includes litigation expense of $136 million in the first fiscal six months of 2015. Includes a gain of $981 million recorded in the fiscal second quarter and first fiscal six months of 2015 from the divestiture of the U.S. license rights to NUCYNTA ® (tapentadol), NUCYNTA ® ER (tapentadol extended-release tablets), and NUCYNTA ® (tapentadol) oral solution. (3) Includes litigation expense of $134 million recorded in the fiscal second quarter of 2015. Includes litigation expense of $276 million and Synthes integration costs of $144 million recorded in the fiscal second quarter of 2014. Includes a net litigation gain of $404 million , $148 million for costs associated with the DePuy ASR TM Hip program and Synthes integration costs of $81 million recorded in the first fiscal six months of 2015. Includes litigation expense of $276 million and Synthes integration costs of $262 million recorded in the first fiscal six months of 2014. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.